Sage Therapeutics
SAGE
#7394
Rank
โ‚ฌ0.30 B
Marketcap
4,93ย โ‚ฌ
Share price
6.60%
Change (1 day)
-72.32%
Change (1 year)

P/E ratio for Sage Therapeutics (SAGE)

P/E ratio as of November 2024 (TTM): -0.5212

According to Sage Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.521169. At the end of 2022 the company had a P/E ratio of -4.25.

P/E ratio history for Sage Therapeutics from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-4.25-22.12%
2021-5.45-173.19%
20207.45-238.11%
2019-5.40-54.66%
2018-11.9-48.56%
2017-23.1112.94%
2016-10.9-36.83%
2015-17.2-22.08%
2014-22.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.8698 66.90%๐Ÿ‡บ๐Ÿ‡ธ USA
1.03-298.13%๐Ÿ‡บ๐Ÿ‡ธ USA
60.6-11,722.51%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
2.97-670.53%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.